Literature DB >> 7852530

Mutations in the RET protooncogene in sporadic pheochromocytomas.

N M Lindor1, R Honchel, S Khosla, S N Thibodeau.   

Abstract

Mutations in the RET protooncogene have recently been demonstrated in families with multiple endocrine neoplasia (MEN) types 2A and 2B. We have studied pheochromocytomas from 29 individuals who had no clinical evidence of MEN-2A or -2B to determine the frequency of germline and/or somatic mutations in exons 10, 11, and 16 of the RET protooncogene. Of the 29 tumors examined, 3 (10%) were found to have a mutation in 1 of the 3 exons. These mutations were not found in the DNA from the peripheral blood from these individuals, indicating that the mutations in the tumors were somatic in origin. Although we cannot exclude the possibility of mutations in other regions of the RET protooncogene, our data suggest that 1) individuals presenting with apparently sporadic pheochromocytomas are not likely to have undiagnosed MEN-2A or -2B; and 2) somatic mutations in exons 10, 11, and 16 in the RET protooncogene contribute to the process of tumorigenesis in a small percentage of sporadic pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852530     DOI: 10.1210/jcem.80.2.7852530

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  RET proto-oncogene mutations and rearrangements in endocrine diseases.

Authors:  R V Lloyd
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 2.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

Review 3.  Hereditary paraganglioma targets diverse paraganglia.

Authors:  B E Baysal
Journal:  J Med Genet       Date:  2002-09       Impact factor: 6.318

Review 4.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

5.  Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.

Authors:  C Eng; P A Crossey; L M Mulligan; C S Healey; C Houghton; A Prowse; S L Chew; P L Dahia; J L O'Riordan; S P Toledo
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

Review 6.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 7.  RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Authors:  Andrea Z Lai; Taranjit S Gujral; Lois M Mulligan
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

8.  Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2.

Authors:  Christian A Koch; David Mauro; McClellan M Walther; W Marston Linehan; Alexander O Vortmeyer; Ronald Jaffe; Karel Pacak; George P Chrousos; Zhengping Zhuang; Irina A Lubensky
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 9.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

10.  Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.

Authors:  C Eng; K A Foster; C S Healey; C Houghton; S A Gayther; L M Mulligan; B A Ponder
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.